[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604576":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":26,"centralContacts":26,"locations":36,"responsibleParty":49,"collaborators":26,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":26,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":79,"whyStopped":26,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Sinai University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Bee Venom Phonophoresis","EXPERIMENTAL","Participants receive bee venom phonophoresis therapy three times per week for the study duration. Ultrasound parameters set at 1 MHz frequency, low-to-moderate intensity, applied in circular or linear motion for 5-10 minutes per sinus. Bee venom is mixed with ultrasound coupling gel and applied to targeted sinus areas.\n\nIntervention Name: Bee Venom Phonophoresis",[13,14],"Device: Bee Venom Phonophoresis","Biological: Bee Venom Phonophoresis",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard Care","PLACEBO_COMPARATOR","Participants receive standard medical treatment for sinusitis, consisting of oral decongestants and saline nasal irrigation, according to local clinical guidelines.",[20],"Drug: Standard Care (oral decongestants + saline nasal irrigation)",[22,27,32],{"type":23,"name":9,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Ultrasound therapy device",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"DRUG","Standard Care (oral decongestants + saline nasal irrigation)","(oral decongestants + saline nasal irrigation)",[16],{"type":33,"name":9,"description":34,"armGroupLabels":35,"otherNames":26},"BIOLOGICAL","bee venom extract prepared for topical use)",[9],[37],{"facility":38,"status":26,"city":39,"state":26,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":26},"Sinai university","Cairo","44511","Egypt","EG",{"type":44,"coordinates":45},"Point",[46,47],31.24967,30.06263,{"lat":47,"lon":46},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Amany Gomaa Atiaa","lecturer","100604576","efficacy-of-bee-venom-phonophoresis-in-treating-chronic-sinusitis-100604576",false,"NCT07151313","Efficacy of Bee Venom Phonophoresis in Treating Chronic Sinusitis:","Efficacy of Bee Venom Phonophoresis in Treating Chronic Sinusitis: A Double-Blind Randomized Controlled Trial","BEE-SONIC","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Clinical diagnosis of chronic sinusitis (symptoms ≥ 12 weeks) or acute sinusitis confirmed by an otolaryngologist.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to bee venom or bee products.\n* Skin conditions (e.g., eczema, dermatitis, open wounds) over the area of ultrasound application.\n* Severe comorbid medical conditions (e.g., uncontrolled asthma, autoimmune disease, malignancy).\n* Pregnancy or breastfeeding.\n* Use of systemic corticosteroids, antibiotics, or other medications that may significantly alter sinusitis symptoms within 4 weeks prior to enrollment.\n* Participation in another clinical trial within the past 30 days.","ALL","18 Years","65 Years",{"count":65,"type":66},30,"ESTIMATED","INTERVENTIONAL",[69],"NA","This double-blind, randomized controlled trial (BEE-SONIC) aims to evaluate the efficacy of bee venom phonophoresis in the treatment of chronic sinusitis. Thirty adult patients (aged 18-65 years) with clinically diagnosed chronic or acute sinusitis will be randomized into two groups: the intervention group will receive bee venom phonophoresis using low-to-moderate intensity ultrasound, while the control group will receive standard care consisting of oral decongestants and saline nasal irrigation. Primary outcomes include improvement in symptom severity (SNOT-22, Visual Analog Scale) and quality of life (SF-33). Secondary outcomes include reduction in facial pain, nasal congestion, and patient satisfaction. Data will be collected at baseline, midpoint, and post-intervention, and analyzed using paired t-tests and ANOVA. The study has received ethics approval from Sinai University's Human Research Ethics Committee, and informed consent will be obtained from all participants.",[72,73,74],"Chronic Sinusitis","Acute Sinusitis","Rhinosinusitis",[76,77,78],"Sinusitis","Rhinosinusitis, Chronic","Rhinosinusitis, Acute","NOT_YET_RECRUITING","2026-05-05",{"date":82,"type":83},"2026-05-11","ACTUAL",{"date":85,"type":66},"2026-05-15",{"date":87,"type":66},"2026-12-25",{"name":5,"class":6},1]